Clinical trials · North Carolina
Cancer clinical trials in North Carolina
We’re tracking 622 recruiting cancer studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Durham, North CarolinaAges 18 years+ - NCT05058508Recruiting
Exercise program for children and young adults on new cancer treatment
This study tests an exercise program for young people newly diagnosed with cancer who are starting treatment like chemotherapy. It aims to see whether safely adding exercise can be part of care during the first treatment cycles.
Charlotte, North CarolinaAges 2–25 - NCT05008848RecruitingPhase 3
Text-based quit smoking program for rural cancer survivors
This trial tests a text message program to help people who have had cancer quit smoking. It is designed for those living in rural areas and aims to see if this program can support them in stopping smoking.
Clemmons, North CarolinaAges 18 years+ - NCT05006482RecruitingPhase 3
Geriatric education and care support for older cancer survivors
This study tests whether a structured health education and “older adult care” approach—done with your oncology team—can improve support for people after cancer. It includes older cancer survivors and a chosen caregiver, using in-person or video visits for follow-up.
Kernersville, North CarolinaAges 18 years+ - NCT04939051RecruitingPhase 2
Obeticholic acid to prevent Barrett’s esophagus worsening
This Phase 2 trial tests whether obeticholic acid (a medicine) can help stop Barrett’s esophagus from getting worse. You must already be taking acid-suppressing medicine and have non-cancer Barrett’s changes, and the study checks safety and whether the lining improves or stays stable.
Chapel Hill, North CarolinaAges 18 years+ - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Hendersonville, North CarolinaAges 18 years+ - NCT04879329RecruitingPhase 2
Study for HER2-positive bladder cancer after limited treatment
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Chapel Hill, North CarolinaAges 18 years+ - NCT04891289RecruitingPhase 2
Gemcitabine and oxaliplatin with a chemotherapy pump for bile duct cancer
This Phase 2 study tests gemcitabine plus oxaliplatin chemotherapy, and whether adding a chemotherapy pump (with floxuridine and dexamethasone) delivered to the liver improves outcomes. It is for people whose intrahepatic cholangiocarcinoma cannot be removed with surgery.
Durham, North CarolinaAges 18 years+ - NCT04858256RecruitingPhase 2
Pacritinib for relapsed or resistant T-cell blood cancers
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
Durham, North CarolinaAges 18 years+ - NCT04840602RecruitingPhase 2
Venetoclax plus rituximab versus standard Waldenstrom treatment
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Charlotte, North CarolinaAges 18 years+ - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Durham, North CarolinaAges 18 years+ - NCT04700527RecruitingPhase 1/Phase 2
Nutritional supplement for reducing side effects from radiation to the belly or pelvis
This trial is studying whether a nutritional supplement (a type of short-chain fatty acid) can help reduce the side effects of radiation therapy for cancers in the abdomen or pelvis. It aims to improve quality of life during treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Durham, North CarolinaAges 18 years+ - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Durham, North CarolinaAges 12–39 - NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Asheboro, North CarolinaAges 18–79 - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Charlotte, North CarolinaAges 1–30 - NCT04566328RecruitingPhase 3
Newly diagnosed multiple myeloma test of combination therapy
This Phase 3 trial tests a combination treatment approach for adults with newly diagnosed multiple myeloma, focusing on response and deeper remission. It may help by improving how well the disease is controlled early and measuring results beyond standard tests.
Kenansville, North CarolinaAges 18 years+ - NCT04511013RecruitingPhase 2
Trial for BRAF-mutant melanoma spread to the brain
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Statesville, North CarolinaAges 18 years+ - NCT04577599Recruiting
Mobile low-dose lung CT screening for ages 40–54
This study offers mobile low-dose CT scans to help find lung problems early in people at higher risk from smoking. You may be invited because of your age and smoking history, and the results may guide next steps with your care team.
Charlotte, North CarolinaAges 40–54 - NCT04564989Recruiting
Biomarker study for HPV-related throat cancer outcomes
This observational study checks how well a blood test for HPV DNA (and other tumor genetic markers) predicts outcomes in certain throat cancers. It may help doctors better track the disease and plan treatment, because the trial validates these lab signals against real-world results.
Chapel Hill, North CarolinaAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Chapel Hill, North CarolinaAges 18 years+ - NCT04364503Enrolling by invitation
Study that analyzes de-identified patient samples and records
This trial checks how well patient samples and health records can be analyzed when names are removed (“de-identified”) and privacy rules are followed. You might be included if you agree in writing and your sample data can be used for this research and/or your doctor requests it.
Burlington, North CarolinaAges Any age - NCT04357574Enrolling by invitation
Testing a radiation treatment decision system during COVID-19 changes
This trial looks at whether a computer system can help guide high-intensity radiation treatment decisions when care has been disrupted during COVID-19. It may help improve how treatment is planned and adjusted during times when patients’ situations change.
Durham, North CarolinaAges 18 years+ - NCT04375384RecruitingPhase 2
Cetuximab after immunotherapy for head and neck cancer
This trial studies whether giving cetuximab after prior immunotherapy can help people with head and neck squamous cell cancer shrink tumors or slow their growth. You may be eligible if you’ve already had a PD-1–based immunotherapy treatment, and you meet health and safety requirements.
Winston-Salem, North CarolinaAges 18 years+
Cancer trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting cancer studies listed above.
- Duke University Medical Center · 8 studies
- Southeastern Medical Oncology Center-Clinton · 6 studies
- Southeastern Medical Oncology Center-Goldsboro · 6 studies
- Southeastern Medical Oncology Center-Jacksonville · 6 studies
- UNC Lineberger Comprehensive Cancer Center · 4 studies
- Durham VA Medical Center · 3 studies
- East Carolina University · 3 studies
- Levine Cancer Institute · 3 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in North Carolina?
- Yes. We're currently tracking 622 recruiting cancer studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.